Media

Washington, D.C. –U.S.

Washington, D.C. –U.S.

Washington, D.C. –U.S. Representatives Mariannette Miller-Meeks (IA-01), Anna Eshoo (CA-16), Michael Burgess (TX-26), Robin Kelly (IL-02), Lisa Blunt Rochester (DE-AL), and Jen Kiggans (VA-02) introduced legislation to improve pregnancy outcomes and infant health by continuing research and education programs aimed at preventing preterm births.

Washington, D.C. – U.S. Representatives Mariannette Miller-Meeks (IA-01), Stephanie Bice (OK-05), Wesley Hunt (TX-13), Eric Sorensen (IL-17), and Nikki Budzinski (IL-13) today introduced the Fuels Parity Act, legislation that would allow ethanol from corn starch to qualify as an advanced biofuel and require EPA to use the Argonne GREET model to determine the greenhouse gas emission profile of biofuels under the RFS.

Washington, D.C. – The Members of Iowa’s Congressional Delegation released the following statement on the debt ceiling package negotiations, which resulted in major concessions to protect Iowa’s farmers.

Washington, D.C. – U.S. Representative Mariannette Miller-Meeks (IA-01) today penned a letter to healthcare industry stakeholders seeking insight as she leads Congressional efforts to reform and improve the Centers for Disease Control and Prevention (CDC).

Washington, D.C. – U.S. Representative Mariannette Miller-Meeks (IA-01) today was joined by her colleagues in the Iowa congressional delegation, U.S. Representatives Ashley Hinson (IA-02), Zach Nunn (IA-03), and Randy Feenstra (IA-04), as well as U.S. Representatives Nikki Budzinski (IL-13), Darin LaHood (IL-16), and Angie Craig (MN-02) in introducing the Next Generation Fuels Act, legislation to phase in higher gasoline octane levels through the greater use of ethanol.

WASHINGTON, D.C. – U.S. Representatives Mariannette Miller-Meeks (IA-01), Greg Murphy (NC-03), Nanette Barragán (CA-44), and Annie Kuster (NH-02) today introduced the Biologics Competition Act, legislation to direct the Secretary of Health and Human Services to evaluate the process by which interchangeable biological products are approved to be used in pharmaceuticals.